^Eligible patients lost an average of 13.6% of their body weight (-31.3 lbs) in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight (-33.6 lbs) in a 68-week clinical trial. Both were paired with diet and exercise
This results in acetaldehyde levels rising sharply within your body
While all of these medications act on the GLP-1 receptor, Trulicity is a mono-agonist, while Mounjaro is a dual agonist, acting on both GLP-1 and GIP receptors
Its main ingredient is L-carnitine, necessary for energy metabolism, it acts as a transporter, allowing fat to be used as an energy source
In attempting to understand whether manipulation of NEP24.11 to prevent the degradation of GLP-1 into GLP-1(2836) would affect the clinically observed cardioprotective actions of GLP-1, we found that the in vitro cAMP response to GLP-1 was lost with addition of the NEP24.11 inhibitor sacubitril